NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free NAMS Stock Alerts $22.74 +0.04 (+0.18%) (As of 10:13 AM ET) Add Compare Share Share Today's Range$22.26▼$22.7550-Day Range$17.60▼$24.2352-Week Range$5.63▼$26.35Volume17,140 shsAverage Volume236,296 shsMarket Capitalization$2.03 billionP/E RatioN/ADividend YieldN/APrice Target$31.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get NewAmsterdam Pharma alerts: Email Address NewAmsterdam Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside36.6% Upside$31.00 Price TargetShort InterestHealthy0.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 6 Articles This WeekInsider TradingSelling Shares$4.10 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.89) to ($1.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.58 out of 5 starsMedical Sector260th out of 939 stocksPharmaceutical Preparations Industry114th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingNewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.00, NewAmsterdam Pharma has a forecasted upside of 36.6% from its current price of $22.70.Amount of Analyst CoverageNewAmsterdam Pharma has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.98% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NewAmsterdam Pharma has recently decreased by 6.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NAMS. Previous Next 2.6 News and Social Media Coverage News SentimentNewAmsterdam Pharma has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for NewAmsterdam Pharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for NAMS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows4 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have sold 4,210.77% more of their company's stock than they have bought. Specifically, they have bought $95,000.00 in company stock and sold $4,095,234.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of NewAmsterdam Pharma is held by insiders.Percentage Held by Institutions89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NewAmsterdam Pharma are expected to grow in the coming year, from ($1.89) to ($1.26) per share.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 6.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert About NewAmsterdam Pharma Stock (NASDAQ:NAMS)NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Read More NAMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAMS Stock News HeadlinesMarch 28, 2024 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $4,095,234.00 in StockMarch 25, 2024 | globenewswire.comNewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 24, 2024 | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up to $22.45March 19, 2024 | seekingalpha.comNAMS NewAmsterdam Pharma Company N.V.March 13, 2024 | msn.comAmring Pharmaceuticals Rebrands as Nordic Pharma, Eyes Global Expansion with Strategic AcquisitionMarch 12, 2024 | globenewswire.comNewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDMarch 1, 2024 | finance.yahoo.comNewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss ExpectationsMarch 28, 2024 | Huge Alerts (Ad)Trending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! February 28, 2024 | finanznachrichten.deNewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | finance.yahoo.comNewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical ProgressFebruary 28, 2024 | globenewswire.comNewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for NewAmsterdam Pharma with Increased Price Target Amid Promising Drug Trials and Strategic InitiativesFebruary 26, 2024 | finance.yahoo.comNewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchFebruary 24, 2024 | msn.comNewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11February 23, 2024 | benzinga.comNewAmsterdam Pharma Stock (NASDAQ:NAMS), Insider Trading ActivityFebruary 20, 2024 | msn.comList of Universities that offer pharmacy in South Africa in 2024February 16, 2024 | finanznachrichten.deNewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 14, 2024 | seekingalpha.comNewAmsterdam Pharma prices $175M share offeringFebruary 14, 2024 | finance.yahoo.comNewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 13, 2024 | globenewswire.comNewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 13, 2024 | finance.yahoo.comNewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 13, 2024 | markets.businessinsider.comBuy Rating on NewAmsterdam Pharma: Underappreciated Potential of Obicetrapib in CVD MarketFebruary 1, 2024 | finance.yahoo.comNewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 16, 2024 | msn.comCholesterol Player NewAmsterdam Pharma's Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst SaysJanuary 8, 2024 | finance.yahoo.comNewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of DirectorsJanuary 4, 2024 | finanznachrichten.deNewAmsterdam Pharma N.V.: NewAmsterdam Pharma Announces 2024 Strategic PrioritiesSee More Headlines Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NAMS CUSIPN/A CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$31.00 High Stock Price Target$37.00 Low Stock Price Target$22.00 Potential Upside/Downside+36.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.95 Quick Ratio6.95 Sales & Book Value Annual Sales$14.09 million Price / Sales143.82 Cash FlowN/A Price / Cash FlowN/A Book Value$3.50 per share Price / Book6.49Miscellaneous Outstanding Shares89,270,000Free Float87,035,000Market Cap$2.03 billion OptionableNot Optionable Beta0.02 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Michael Harvey Davidson FACC (Age 68)Facp., M.D., CEO, President, Executive Board Member & Director Comp: $882kDr. Johannes Jacob Pieter Kastelein FESC (Age 70)M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director Comp: $677.76kMr. Mayur Amrat Somaiya (Age 51)Chief Financial Officer Comp: $130.58kMr. Douglas F. Kling (Age 51)Chief Operating Officer Mr. Jim JacobsonChief Legal Officer & SecretaryDr. Marc Ditmarsch M.D. (Age 57)Chief Development Officer Dr. Sheng Cui Ph.D.VP & Head of Chemistry Manufacturing and Controls (CMC)Ms. Annie NeildVP & Head of Regulatory AffairsMr. William Jones Jr. (Age 60)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsJanux TherapeuticsNASDAQ:JANXAmphastar PharmaceuticalsNASDAQ:AMPHStructure TherapeuticsNASDAQ:GPCRMaravai LifeSciencesNASDAQ:MRVIAvidity BiosciencesNASDAQ:RNAView All CompetitorsInsiders & InstitutionsJohannes Jacob Piete KasteleinSold 190,476 sharesTotal: $4.10 M ($21.50/share)Fcpm Iii Services B.V.Bought 11,831,461 shares on 3/7/2024Ownership: 14.373%Goldman Sachs Group Inc.Bought 1,384,321 shares on 3/1/2024Ownership: 1.682%Parkman Healthcare Partners LLCBought 51,726 shares on 2/15/2024Ownership: 0.369%Opaleye Management Inc.Bought 265,388 shares on 2/15/2024Ownership: 0.325%View All Insider TransactionsView All Institutional Transactions NAMS Stock Analysis - Frequently Asked Questions Should I buy or sell NewAmsterdam Pharma stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NAMS shares. View NAMS analyst ratings or view top-rated stocks. What is NewAmsterdam Pharma's stock price target for 2024? 6 Wall Street research analysts have issued 1-year target prices for NewAmsterdam Pharma's shares. Their NAMS share price targets range from $22.00 to $37.00. On average, they anticipate the company's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 36.6% from the stock's current price. View analysts price targets for NAMS or view top-rated stocks among Wall Street analysts. How have NAMS shares performed in 2024? NewAmsterdam Pharma's stock was trading at $11.17 at the beginning of the year. Since then, NAMS stock has increased by 103.2% and is now trading at $22.70. View the best growth stocks for 2024 here. When is NewAmsterdam Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our NAMS earnings forecast. Who are NewAmsterdam Pharma's major shareholders? NewAmsterdam Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fcpm Iii Services B.V. (14.37%), Goldman Sachs Group Inc. (1.68%), Goldman Sachs Group Inc. (1.70%), Parkman Healthcare Partners LLC (0.37%), Opaleye Management Inc. (0.33%) and Citadel Advisors LLC (0.03%). Insiders that own company stock include Johannes Jacob Piete Kastelein and Louis G Lange. View institutional ownership trends. How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NAMS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.